Development of shigella sonnei live oral vaccines based on defined rfbInaba deletion mutants of vibrio cholerae expressing the shigella serotype D O polysaccharide

Infection and Immunity

Volumn 64, Issue 2, 1996, Pages 576-584

  Favre, Didier ^a   Cryz Jr , Stanley J ^a   Viret, Jean François ^a  

^a Berna Biotech AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CHOLERA VACCINE; ENTEROTOXIN; LIPOPOLYSACCHARIDE; LIVE VACCINE; MERCURY; POLYSACCHARIDE; SYNTHETASE; TETRONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CHROMOSOME; CONTROLLED STUDY; DELETION MUTANT; GENE; GENE DISRUPTION; IMMUNIZATION; IMMUNOBLOTTING; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE CONTRAST MICROSCOPY; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SHIGELLA SONNEI; VIBRIO CHOLERAE;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CLONING, MOLECULAR; GENE DELETION; GENETIC VECTORS; IMMUNIZATION; MICE; O ANTIGENS; SHIGELLA SONNEI; VACCINES, SYNTHETIC; VIBRIO CHOLERAE;

EID: 0030034113     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.64.2.576-584.1996     Document Type: Article

References (68)

1. Attridge, S. R., D. Daniels, J. K. Morona, and R. Morona. 1990. Surface co-expression of Vibrio cholerae and Salmonella typhi O-antigens on Ty21d clone EX210 Microb Pathog. 8:177-188.
2. Attridge, S. R., C. Dearlove, L. Beyer, L. van den Bosch, A. Howles, J. Hackett, R. Morona, J. LaBrooy, and D. Rowley. 1991. Characterization and immunogenicity of EX880, a Salmonella typhi Ty21a-based clone which produces Vibrio cholerae O antigen. Infect. Immun. 59:2279-2284.
3. Black, R. E. 1993. Epidemiology of diarrhoeal disease: implications for control by vaccines. Vaccine 11:100-106.
4. Black, R. E., M. M. Levine, M. L. Clements, G. Losonsky, D. Herrington. S. Herman, and S. B. Formal. 1987. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine J Infect. Dis. 155:1260-1265.
5. Brahmbhatt, H. N., A. A. Lindberg, and K. N. Timmis. 1992. Shigella lipopolysaccharide structure, genetics, and vaccine development. Curr. Top Microbiol. Immunol. 180:45-63.
6. Cárdenas, L., and J. D. Clements. 1992 Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clin. Microbiol. Rev 5:328-342.
7. - cloning vectors. I. Improved pUC polylinker regions to facilitate the use of sonicated DNA for nucleotide sequencing. Gene 68:139-149
8. Coster, T. S., K. P. Killeen, M. K. Waldor, D. T. Beattie, D. R. Spriggs, J. R. Kenner, A. Trofa, J. C. Sadoff, J. J. Mekalanos, and D. N. Taylor. 1995. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype Lancet 345:949-952.
9. Cryz, S. J., Jr., T. L. Pitt, E. Fürer, and R. Germanier. 1984. Role of lipopolyaaccharide in virulence of Pseudomonas aeruginosa Infect. Immun 44:508-513.
10. Curtiss, R., III. 1990. Attenuated Salmonella strains as live vectors for the expression of foreign antigens, p. 161-188. In G C. Woodrow and M M. Levine (ed.), New generation vaccines Marcel Dekker Inc., New York
11. Czerkinsky, C., A.-M. Svennerholm, M. Quiding, R. Jonsson, and J. Holmgren. 1991. Antibody producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect. Immun. 59:996-1001.
12. DuPont, H. L., R. B. Hornick, M. J. Synder, J. P. Libonati, S. B. Formal, and E. J. Gangarosa. 1972. Immunity in shigellosis. I. Response of man to attenuated strains of Shigella. J. Infect. Dis. 125:5-11.
13. DuPont, H. L., R. B. Hornick, M. J. Snyder, J. P. Libonati, S. B. Formal, and E. J. Gangarosa. 1972. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection J. Infect. Dis. 125:12-16.
14. Evans, D. G., D. J. Evans, Jr., and W. Tjoa. 1977. Hemagglutination of human group A erythrocytes by enterotoxigenic Escherichia coli isolated from adults with diarrhea correlation with colonization factor Infect. Immun. 18:330-337.
15. Favre, D. 1992. Improved phenol-based method for the isolation of DNA fragments from low-melting temperature agarose gels. BioTechniques 13:22-26.
16. Favre, D., M. M. Struck, S. J. Cryz, Jr., and J.-F. Viret. Further molecular characterization and stability of the live oral attenuated cholera vaccine strain CVD103-HgR. Vaccine, in press.
17. Fontaine, A., J. Arondel, and P. J. Sansonetti. 1990. Construction and evaluation of live attenuated vaccine strains of Shigella flexneri and Shigella dysenteriae 1. Res. Microbiol. 141:907-912.
18. Formal, S. B., T. L. Hale, C. Kapfer, J. P. Cogan, P. J. Snoy, R. Chung, M. E. Wingfield, B. L. Elisberg, and L. S. Baron. 1984. Oral vaccination of monkeys with an invasive Escherichia coli K-12 hybrid expressing Shigella flexneri 2a somatic antigen. Infect. Immun. 46:465-469
19. Forrest, B. D., and J. T. LaBrooy. 1991. In vivo evidence of immunological masking of the Vibrio cholerae O antigen of a hybrid Salmonella typhi Ty21a-Vibrio cholerae oral vaccine in humans. Vaccine 9:515-520.
20. Fralick, J. A., and L. L. Burns-Keliher. 1994. Additive effect of tolC and rfa mutations on the hydrophobic barrier of the outer membrane of Escherichia coli K-12. J. Bacteriol. 176:6404-6406.
21. Fuerst, J. A., and J. W. Perry. 1988. Demonstration of lipopolysaccharide on sheathed flagella of Vibrio cholerae O:1 by protein A-gold immunoelectron microscopy J. Bacteriol. 170:1488-1494.
22. Germanier, R., and E. Furer. 1975. Isolation and characterization of galE mutant Ty21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine J. Infect. Dis. 131:553-558
23. Giannasca, P. J., and M. R. Neutra. 1994. Interactions of microorganisms with intestinal M cells: mucosal invasion and induction of secretory immunity. Infect Agents Dis. 2:242-248.
24. Gustafsson, B., and T. Holme. 1983. Monoclonal antibodies against groupand type-specific lipopolysaccharide antigens of V. cholerae O:1. J Clin. Microbiol. 18:480-485.
25. Hale, L. H., and S. B. Formal. 1990. Live oral vaccines consisting of Escherichia coli or Salmonella typhi expressing Shigella antigens, p. 667-676. In G. C. Woodrow and M. M Levine (ed.), New generation vaccines Marcel Dekker Inc., New York.
26. Hartman, A. B., M. M. Ruiz, and C. L. Schultz. 1991. Molecular analysis of variant plasmid forms of a bivalent Salmonella typhi-Shigella sonnet vaccine strain J. Clin. Microbiol. 29:27-32
27. Herrington, D. A., L. Van De Verg, S. B. Formal, T. L. Hale, B. D. Tall, S. J. Cryz, Jr., E. C. Tramont, and M. M. Levine. 1990 Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease Vaccine 8:353-357.
28. Jann, B., K. Jann, and G. O. Bayert. 1973, 2-Amino-2,6-dideoxy-D-glucose (D-quinovosamine): a constituent of the lipopolysaccharides of Vibrio cholerae. Eur J. Biochem. 37:531-534
29. Jansson, P.-E., A. A. Lindberg, B. Lindberg, and R. Wollin. 1981. Structural studies on the hexose region of the core in lipopolysaccharides from Enterobacteriaceae. Eur. J Biochem. 115:571-577.
30. Kabir, S., and S. Ali. 1983 Characterization of surface properties of Vibrio cholerae. Infect. Immun. 39:1048-1058
31. Kaper, J. B., J. G. Morris, Jr., and M. M. Levine. 1995. Cholera. Clin. Microbiol. Rev. 8:48-86
32. Karnell, A., A. Li, C. R. Zhao, K. Karlsson, N. B. Minh, and A. A. Lindberg. 1995. Safety and immunogenicity study of the auxotrophic Singella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers Vaccine 13:88-99.
33. Keen, N. T., S. Tamaki, D. Kobayashi, and D. Trollinger. 1988 Improved broad-host-range plasmids for DNA cloning in gram-negative bacteria. Gene 70:191-197.
34. Kenne, L., B. Lindberg, K. Petersson, E. Katzenellenbogen, and E. Romanowska. 1980. Structural studies of the O-specific side-chains of the Shigella sonnei phase I lipopolysaccharide Carbohydr. Res. 78:119-126.
35. Kenne, L., B. Lindberg, P. Unger, T. Holme, and J. Holmgren. 1982. Structural studies of the Vibrio cholerae O-antigen. Carbohydr. Res. 100:341-349.
36. Ketley, J. M., J. Michalski, J. Galen, M. M. Levine, and J. B. Kaper. 1993. Construction of genetically marked Vibrio cholerae O1 vaccine strains. FEMS Microbiol. Lett. 111:15-22.
37. Kondo, S., T. Iguchi, and K. Hisatsune. 1988. A comparative study of the sugar composition of lipopolysaccharides isolated from Vibrio cholerae, "Vibrio albensis" and Vibrio meischnikovu. J. Gen Microbiol. 134:1699-1705.
38. Laird, M. W., A. W. Kloser, and R. Misra. 1994. Assembly of LamB and OmpF in deep rough lipopolysaccharide mutants of Escherichia coli K-12. J. Bacteriol. 176:2259-2264.
39. Levine, M. M., and J. B. Kaper. 1993 Live oral vaccines against cholera: an update Vaccine 11:207-212.
40. Levine, M. M., and C. O. Tacket. 1994. Recombinant live cholera vaccines, p. 395-413. In I. K Wachsmuth. P A. Blake, and Ø. Olsvik (ed.). Vibrio cholerae and cholera: molecular to global perspectives. American Society for Microbiology, Washington, D.C.
41. Lindberg, A. A., A. Karnell, and B. A. D. Stocker. 1990. Aromatic-dependent Shigella strains as live oral vaccines, p. 677-687. In G. C. Woodrow and M M. Levine (ed.), New generation vaccines. Marcel Dekker Inc., New York
42. Lindberg, A. A., and T. Pal. 1993. Strategies for development of potential candidate Shigella vaccines. Vaccine 11:168-179.
43. Lüderitz, O., M. A. Freudenberg, C. Galanos, V. Lehmann, E. T. Rietschel, and D. H. Shaw. 1982. Lipopolysaccharides of gram-negative bacteria. Curr. Top. Membr. Transp. 17:79-151
44. Manning, P. A., U. H. Stroeher, L. E. Karageorgos, and R. Morona. 1995. Putative O-antigen transport genes within the rfb region of Vibrio cholerae O1 are homologous to those for capsule transport. Gene 158:1-7.
45. Manning, P. A., U. H. Stroeher, and R. Morona. 1994. Molecular basis for O-antigen biosynthesis in Vibrio cholerae O1: Ogawa-Inaba switching, p. 77-94. In K. Wachsmuth, P. A. Blake, and Ø. Olsvik (ed), Vibrio cholerae and cholera: molecular to global perspectives. American Society for Microbiology, Washington, D.C.
46. Maurelli, A. T., and P. J. Sansonetti. 1988. Genetic determinants of Shigella pathogenicity. Annu. Rev. Microbiol. 42:127-150.
47. Miller, J. H. 1972 Experiments in molecular genetics, p 431-433. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
48. Nikaido, H., and M. Vaara. 1985 Molecular basis of bacterial outer membrane permeability. Microbiol Rev. 49:1-32.
49. Noriega, R. N., J. Y. Wang, G. Losonsky, D. R. Maneval, D. M. Hone, and M. M. Levine. 1994. Construction and characterization of attenuated ΔaroA ΔvirG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine Infect. Immun. 62:5168-5172.
50. Orr, N., G. Robin, D. Cohen, R. Arnon, and G. H. Lowell. 1993. Immunogenicity and efficacy of oral and intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models Infect. Im-mun. 61:2390-2395.
51. Owen, R. L., N. F. Pierce, R. T. Apple, and W. C. Cray. 1986. M cell transport of Vibrio cholerae from the intestinal lumen into Peyer's patches, a mechanism for antigen sampling and for microbial transepithehal migration J. Infect. Dis. 153:1108-1118.
52. Pitcher, D. G., N. A. Saunders, and R. J. Owen. 1989. Rapid extraction of bacterial genomic DNA with guanidium thiocyanate. Lett. Appl Microbiol. 8:151-156.
53. Redmond, J. W. 1975. 4-Amino-1,6-dideoxy-D-mannose (D-perosamine): a component of the lipopolysaccharide of Vibrio cholerae 569B (Inaba). FEBS Lett. 50:147-149.
54. Ried, G., I. Hindennach, and U. Henning. 1990. Role of lipopolysaccharide in assembly of Escherichia coli outer membrane proteins OmpA, OmpC. and OmpF. J. Bacteriol. 172:6048-6053.
55. Sack, D. A., and R. B. Sack. 1975. Test for enterotoxigemc Escherichia coli using Y1 adrenal cells in miniculture. Infect Immun 11:334-336.
56. Sambrook, J., E. F. Fritsch, and T. Maniafis. 1989 Molecular cloning a laboratory manual. 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
57. Sandlin, R. C., K. A. Lampel, S. P. Keasler, M. B. Goldberg, A. L. Stolzer, and A. T. Maurelli. 1995. Avirulence of rough mutants of Shigella flexneri requirement of O antigen for correct unipolar localization of IcsA in the bacterial outer membrane. Infect. Immun. 63:229-237.
58. Sansonetti, P. J., D. J. Kopecko, and S. B. Formal. 1981 Shigella sonnei plasmids: evidence that a large plasmid is necessary for virulence. Infect Immun. 34:75-83
59. Seid, R. C., Jr., D. J. Kopecko, J. C. Sadoff, H. Schneider, L. S. Baron, and S. B. Formal. 1984. Unusual lipopolysaccharide antigens of a Salmonella typhi oral vaccine strain expressing the Shigella sonnei form I antigen. J. Biol. Chem. 14:9028-9034.
60. Simon, R., U. Priefer, and A. Pühler. 1983. A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in gram negative bacteria. Bio/Technology 1:784-791
61. Svennerholm, A.-M., and J. Holmgren. 1978 Identification of Escherichia coli heat-labile enterotoxin by means of a ganglioside immunosorbent assay (GM1-ELISA) procedure. Curr. Microbiol. 1:19-23.
62. Taylor, D. N., K. P. Killeen, D. C. Hack, J. R. Kenner, T. S. Coster, D. T. Beattie, J. Ezzell, T. Hyman, A. Trofa, M. H. Sjogren, A. Friedlander, J. J. Mekalanos, and J. C. Sadoff. 1994. Development of a live, oral, attenuated vaccine against El Tor cholera. J. Infect. Dis. 170:1518-1523.
63. Taylor, D. N., A. C. Trofa, J. Sadoff, C. Chu, D. Bryla, J. Shiloach, D. Cohen, S. Ashkenazi, Y. Lerman, W. Egan, R. Schneerson, and J. B. Robbins. 1993. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnet (Plestomonas shigelloides) bound to bacterial toxoids. Infect. Immun. 61:3678-3687.
64. Viret, J.-F., U. Bruderer, and A. B. Lang. 1992 Characterization of the Shigella serotype D (S. sonnet) O polysaccharide and the enterobacterial R1 lipopolysaccharide core by use of mouse monoclonal antibodies. Infect. Immun 60:2741-2747.
65. Viret, J.-F., S. J. Cryz, and D. Favre. Expression of Shigella sonnei lipopolysaccharide in Vibrio cholerae. Mol. Microbiol., in press.
66. Viret, J.-F., S. J. Cryz, Jr., A. B. Lang, and D. Favre. 1993. Molecular cloning and characterization of the genetic determinants that express the complete Shigella serotype D (Shigella sonnei) lipopolysaccharide in heterologous live attenuated vaccine strains. Mol. Microbiol. 7:239-252
67. Viret, J.-F., and D. Favre. 1994. Bivalent vaccines against bacterial enteropathogens: construction of live attenuated vaccine strains with two O-serotype specificities. Biologicals 22:361-372.
68. World Health Organization. 1991. Research priorities for diarrhoeal disease vaccines: memorandum from a WHO meeting Bull. W.H.O. 69:667-676